Home›Trial›NCT06161584
NCT06161584ACTIVE NOT RECRUITING

A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Study Summary

A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Conditions
Geographic Atrophy
Interventions / Drugs
Pegcetacoplan
View on ClinicalTrials.gov ↗
Sponsor
APLS
Apellis Pharmaceuticals
Complement Inhibitors
D37/100
Study Details
Enrollment300 participants
Primary Completion—
Lead SponsorApellis Pharmaceuticals, Inc.
Data Retrieved2026-04-11 02:54:08.046086+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.

Enrolled: 300 participants
Sponsor Catalyst Profile

Apellis Pharmaceuticals (APLS) is the sponsoring company for this trial. BiotechSign currently grades this company D (37/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

APLS Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.